NL-OMON42865已完成不适用
A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN HEALTHY VOLUNTEERS TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING SINGLE AND MULTIPLE DOSES OF SNDX-6352 OR PLACEBO ADMINISTERED BY INTRAVENOUS (I.V.) INFUSION - SNDX-6352-0001 SAD and MAD study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Healthy males or females, 18-55 years old, inclusive, at screening. Body Mass Index (BMI): 19.0-30.0 kg/m2, inclusive. Weight: 50-100 kg, inclusive.
排除标准
- •Suffering from hepatitis B, hepatitis C, or HIV/AIDS. In case of participation in another drug study 60 days before the start of this study or being a blood donor within 60 days from the start of the study. Donation or loss of more than 1.5 liters of blood (for male subjects) / more than 1.0 liters of blood (for female subjects) in the 10 months prior to (the first) drug administration in the current study.
研究者
相似试验
已完成
不适用
A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN HEALTHY VOLUNTEERS TO DETERMINE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING MULTIPLE DOSES OF MMI-0100 OR PLACEBO ADMINISTERED BY PULMONARY DELIVERYIdiopathische FibroseIdiopathic pulmoary fibrosispulmonary diseasesNL-OMON43064Moerae Matrix, Inc32
已完成
不适用
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ALTERNATING PANEL, SINGLE ASCENDING DOSE STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF JTK-656 AND THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF JTK-656 IN HEALTHY MALE SUBJECTSimmune deficiency infections10021460NL-OMON32420Japan Tobacco Inc.36
已完成
不适用
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-DOSE ESCALATION, MULTIPLE-DOSE ESCALATION, AND FOOD EFFECT STUDY OF FLX475 IN HEALTHY MALE AND FEMALE SUBJECTSNL-OMON44307FLX Bio, Inc.104
已完成
不适用
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING DOSE STUDY EVALUATING THE SAFETY, TOLERABILITY AND PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF JTK-652 ADMINISTERED FOR FOUR WEEKS IN SUBJECTS WITH CHRONIC HEPATITIS C INFECTIONL-OMON31911Japan Tobacco Inc.20
招募中
1 期
STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF REVN24 IN HEALTHY MALE VOLUNTEERSJPRN-jRCT2071230074Megumi Kai179